PL EN


Preferences help
enabled [disable] Abstract
Number of results
2001 | 55 | 3 | 419-432
Article title

GP IIb/IIIa receptor antagonists ? molecular and clinical aspects

Authors
Title variants
Languages of publication
EN
Abstracts
EN
Recently many investigators have found that platelet glycoprotein GP IIb/IIIa is responsible for platelet aggregation and plays a pivotal role in acute coronary thrombosis. Thus, GP IIb/IIIa antagonists may play an important role by inhibiting platelet aggregation and their binding to fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases and acute coronary syndrome. Now, there are three group of platelet receptor antagonists: monoclonal antibodies, synthetic peptides and non-peptide antagonists. As a result of large clinical trials the potency of those compounds in preventing of coronary thrombosis have been demonstrated. In this article molecular aspects of GP antagonists action and selected clinical trials have been presented.
Publisher

Year
Volume
55
Issue
3
Pages
419-432
Physical description
Contributors
author
References
Document Type
ARTICLE
Publication order reference
T. Francuz, ul. Gliwicka 218a/1, 40-860 Katowice, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-2cffa062-97a5-3bc9-9e96-c5dcf30a3b07
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.